FINAL PROGRAM. ASCO Direct. Current Update CME HOURS. SCfHS ACCREDITED FOR.

ASCO Direct Current Update 2017 24-25 November 2017 Crowne Plaza Hotel, Jeddah, KSA FINAL PROGRAM Organized by: SCfHS ACCREDITED FOR 15CME HOURS Licensed by: Sponsored by: (+966) 11 462 2515 Ext. 14 (+966) 53 390 0404 slca.lca.sts@gmail.com

welcome message The Lung Cancer Academy was established on October 5, 2013 under the Saudi Lung Cancer Association (SLCA) of the Saudi Thoracic Society (STS) To lead the educational and training activities of health care professionals in Thoracic Oncology field including screening and prevention, diagnosis, management and research. To become a regional and international leader in health care professional training and development in the field of Thoracic Oncology. Dear Colleagues, It is my pleasure to welcome you to ASCO Direct Current Update 2017, which will be held at Crowne Plaza Hotel, Jeddah, KSA, on 24-25 November 2017. This two days intensive program has been selected from the most recent congress of the American Society of Clinical Oncology, (2017 ASCO Annual Meeting), which was held in Chicago, 2-6 June 2017. In this event, the scientific committee aims is to provide an attractive scientific program with enhanced scientific content to provide the latest developments, medical advances, cutting edge and breakthroughs in Immuno-Oncology, Lung Cancer, and some other selected oncology topics. In this year s program you will find the latest updates from ASCO2017, including but not limited to: Recent advances in Management of Early Stage Lung Cancer Immuno-Oncology in Lung Cancer Management of EGFRmut and ALK Translocations New targets and New Therapies of Lung Cancer Recent Advances in Immuno-Oncology We hope that you will find the symposium very productive and helpful and we would appreciate all your comments and feedback. The Scientific/ Organizing Committee of ASCO Direct Current Update 2017 look forward to welcoming you at the meeting. Thank you and Best Regards, Immuno-Oncology in GastroIntestinal Malignancies Immuno-Oncology in Genitourinary Malignancies Immuno-Oncology in Hematological Malignancies Immuno-Oncology in Other Solid Tumors Educational modules for all health care professionals including primary care physicians. Educational modules for all subspecialties involved in the management of Lung Cancer (pulmonary, imaging, interventional radiology, pathology, surgery, radiation oncology, medical oncology and palliative care) Prof. Abdul Rahman Jazieh, MD, MPH Chairman, ASCO Direct Current Update 2017 (ASCO2017) Chairman, Saudi Lung Cancer Association/ Lung Cancer Academy Chairman, Oncology Department Professor, King Saud University for Health Sciences King Abdulaziz Medical City (KAMC) King Abdullah Specialized Children s Hospital (KASCH) Ministry of National Guard Health Affairs Courses for physicians-in-training from related specialties. Topics will be covered including: prevention, screening, diagnosis and workup, management, palliation, research and evidence based medicine. 1

GENERAL INFORMATION ABOUT JEDDAH Committee GENERAL INFORMATION Jeddah is a city in the Hijaz Tihamah region on the coast of the Red Sea and is the major urban center of western Saudi Arabia. It is the largest city in Makkah Province, the largest sea port on the Red Sea, and the second-largest city in Saudi Arabia after the capital city, Riyadh. With a population currently at 5.1 million, Jeddah is an important commercial hub in Saudi Arabia. Jeddah is the principal gateway to Mecca, Islam s holiest city, which able-bodied Muslims are required to visit at least once in their lifetime. It is also a gateway to Medina, the second holiest place in Islam. Economically, Jeddah is focusing on further developing capital investment in scientific and engineering leadership within Saudi Arabia, and the Middle East. Jeddah was independently ranked fourth in the Africa Mid-East region in terms of innovation in 2009 in the Innovation Cities Index. Jeddah is one of Saudi Arabia s primary resort cities and was named a Gamma world city by the Globalization and World Cities Study Group and Network (GaWC). Historically, Jeddah has been well known for its legendary money changers. The largest of said money changers at the time (the late Sheikh Salem Bin Mahfouz) eventually founded Saudi Arabia s first bank, the National Commercial Bank (NCB). Climate Jeddah features an arid climate under Koppen s climate classification. Unlike other Saudi Arabian cities, Jeddah retains its warm temperature in winter, which can range from 15 C (59 F) at dawn to 28 C (82 F) in the afternoon. Summer temperatures are extremely hot, often breaking the 43 C (109 F) mark in the afternoon and dropping to 30 C (86 F) in the evening. Rainfall in Jeddah is generally sparse, and usually occurs in small amounts in November and December. Heavy thunderstorms are common in winter. The thunderstorm of December 2008 was the largest in recent memory, with rain reaching around 3 inches (7.6 cm). The lowest temperature ever recorded in Jeddah was 11.0 C (51.8 F) in March 1983. The highest temperature ever recorded in Jeddah was 49.0 C (120.2 F) on June 9, 1961. Dust storms happen in summer and sometimes in winter, coming from the Arabian Peninsula s deserts or from North Africa. Economy Jeddah has long been a port city. Even before being designated the port city for Mecca, Jeddah was a trading hub for the region. In the 19th century, goods such as mother-of-pearl, tortoise shells, frankincense, and spices were routinely exported from the city. Apart from this, many imports into the city were destined for further transit to the Suez, Africa, or Europe. Many goods passing through Jeddah could not even be found in the city or even in Arabia. All of the capitals of the Middle East and North Africa are within two hours flying distance of Jeddah, making it the second commercial center of the Middle East after Dubai. Also, Jeddah s industrial district is the fourth largest industrial city in Saudi Arabia after Riyadh, Jubail and Yanbu. Culture Religious Significance Most citizens are Sunni Muslims. The government, courts and civil and criminal laws enforce a moral code established by Shari ah. A very small minority of Saudi citizens is Shia Muslims, and there is also a large foreign workforce who is forbidden to follow their non-islamic religions even privately, but this is little enforced. The city has over 1,300 mosques. The law does not allow other religions buildings, books, icons and expressions of faith. However, private religious observance not involving Muslims nor offending public order and morality is sometimes tolerated. Since the 7th century, Jeddah has hosted millions of Muslim pilgrims from all over the world on their way to Hajj. This merge with pilgrims has a major impact on the society, religion, and economy of Jeddah. It also brings an annual risk of illness, known by locals as the hajji disease, a general term for various viral maladies. Landmarks King Fahd s Fountain King Fahd s Fountain was built in the 1980s, can be seen from a great distance and, at 312 metres (1,024 ft), is the highest water jet in the world according to the Guinness World Records. The fountain was donated to the City of Jeddah by the late King Fahd bin Abdul Aziz, after whom it was named. Entrance of Makkah The Makkah Gate, named the Quran Gate, is located on the Makkah Mukkarram road of the Jeddah-Makkah Highway. It is the entrance to Makkah and the birthplace of Muhammad. The gate signifies the boundary of the haram area of the city of Makkah, where non-muslims are prohibited to enter.the gate was designed in 1979 by an Egyptian architect, Samir Elabd, for the architectural firm IDEA Center. The structure is that of a book, representing the Qur an, sitting on a rehal, or book stand. Badges: Name badges must be visible and used at all times, anywhere at the conference venue, and off- site social activities. Colors: Green: Red: Light Blue: Yellow: Description: Faculty (all access) Delegate (all access) Exhibitor (all access) Organizer (all access) CME Certification: This Conference is accredited by The Saudi Commission for Health Specialties (SCFHS) for 15 CMEs. In order to receive the CMEs, it is required to fill in the Evaluation and CME Acquisition Form which will be available at the Registration Desk throughout the conference. Though Certificate of Attendance hard copies are not accepted by the SCFHS, but if you like to have one, kindly request through our website. Conference Packets: Conference Packets will be distributed to registered participants at the Registration Desk. Faculty Check in: There is a dedicated faculty lounge & preview room for faculty s registration and badge collection and is operational at the same time as the registration desks. Food & Beverage: Coffee breaks and lunch will be open to registered delegates. The hotel also offers a variety of all day dining restaurants to choose from. Anybody with Conference badge are eligible to go the designated restaurants within the hotel. Automated Teller Machines (ATM): There is an ATM located in the Hotel Lobby Rules: Smoking Policy in the Hotel: The entire hotel is non smoking. Mobile Phones- Delegates are kindly requested to keep their mobile phones in the off mode in meeting rooms when scientific sessions are in progress. Parking: 24 hours valet parking is available at the Conference venue. Prayer Room: Prayer rooms are available in the Event Centre. Evacuation Assembly Point: In case of an emergency evacuation procedure please proceed in an orderly fashion to the open area in front of the Events Centre. Please follow the instructions of the Hotel Staff Wardens at all times. 2 3

Give Your Patients the OPDIVO Opportunity In KSA Opdivo SPC approved by SFDA,SEPT.-2017 OPDIVO (NIVOLUMAB) PRESCRIBING INFORMATION See Summary of Product Characteristics before prescribing. PRESENTATION: single-use vials 40 mg/4 ml (10 mg/ml) and 100 mg/10 ml (10 mg/ml) Solution for Injection Nivolumab. INDICATIONS: OPDIVO as a single agent is indicated for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma. OPDIVO as a single agent is indicated for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma and disease progression following ipilimumab. OPDIVO, in combination with ipilimumab, is indicated for the treatment of patients with unresectable or metastatic melanoma.opdivo is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. OPDIVO is indicated for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. OPDIVO is indicated for the treatment of patients with classical Hodgkin lymphoma (chl) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and post-transplantation brentuximab vedotin. OPDIVO is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy. OPDIVO is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy and who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy, This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.dosage: The recommended dose of OPDIVO is 240 mg administered as an intravenous infusion over 60 minutes every 2 weeks until disease progression or unacceptable toxicity in Melanoma, NSCLC, RCC & ubc. The recommended dose of OPDIVO is 3 mg/kg administered as an intravenous infusion over 60 minutes every 2 weeks until disease progression or unacceptable toxicity in chl & SCCHN. The recommended dose of OPDIVO is 1 mg/kg administered as an intravenous infusion over 60 minutes, followed by ipilimumab on the same day, every 3 weeks for 4 doses. The recommended subsequent dose of OPDIVO, as a single agent, is 240 mg administered as an intravenous infusion over 60 minutes every 2 weeks until disease progression or unacceptable toxicity in Melanoma. CONTRAINDICATIONS: None. SPECIAL WARNINGS AND PRECAUTIONS FOR USE: Severe pneumonitis or interstitial lung disease, including fatal cases, occurred with OPDIVO treatment. Across the clinical trial experience in 691 patients with solid tumors, fatal immune-mediated pneumonitis occurred in 0.7% (5/691) of patients receiving OPDIVO. No cases of fatal pneumonitis occurred in Trial 1 or Trial 3; all five fatal cases occurred in a dose-finding study with OPDIVO doses of 1 mg/kg (two patients), 3 mg/kg (two patients), and 10 mg/kg (one patient). Severe diarrhea or colitis has occurred with OPDIVO treatment. Monitor patients for immune-mediated colitis. Severe hepatitis has occurred with OPDIVO treatment. Monitor patients for abnormal liver tests prior to and periodically during treatment. Severe nephritis or renal dysfunction has occurred with OPDIVO treatment. Monitor patients for elevated serum creatinine prior to and periodically during treatment. Hypothyroidism or hyperthyroidism has occurred with OPDIVO treatment. Monitor thyroid function prior to and periodically during treatment. Other clinically significant immune-mediated adverse reactions can occur. Immune-mediated adverse reactions may occur after discontinuation of OPDIVO therapy. EMBRYOFETAL TOXICITY Based on its mechanism of action and data from animal studies, OPDIVO can cause fetal harm when administered to a pregnant woman. DRUG INTERACTIONS: No formal pharmacokinetic drug-drug interaction studies have been conducted with OPDIVO. Geriatric Use Clinical studies of OPDIVO did not include su_cient numbers of patients aged 65 years and older to determine whether they respond di_erently from younger patients. Pediatric population: Safety and e_ectiveness of OPDIVO have not been established in pediatric patients. FERTILITY, PREGNANCY AND LACTATION OPDIVO is not recommended during pregnancy or in women of childbearing potential not using e_ective contraception, unless the clinical benefit outweighs the potential risk. Pregnancy Category C. UNDESIRABLE EFFECTS: Trial 1 OPDIVO was discontinued for adverse reactions in 9% of patients. Twenty-six percent of patients receiving OPDIVO had a drug delay for an adverse reaction. Serious adverse reactions occurred in 41% of patients receiving OPDIVO. Grade 3 and 4 adverse reactions occurred in 42% of patients receiving OPDIVO. The most frequent Grade 3 and 4 adverse reactions reported in 2% to less than 5% of patients receiving OPDIVO were abdominal pain, hyponatremia, increased aspartate aminotransferase, and increased lipase. In melanoma Trial 1, the most common adverse reaction in patients receiving OPDIVO (reported in at least 20% of patients) was rash. Trial 3 OPDIVO was discontinued due to adverse reactions in 27% of patients. Twenty-nine percent of patients receiving OPDIVO had a drug delay for an adverse reaction. Serious adverse reactions occurred in 59% of patients receiving OPDIVO. The most frequent serious adverse reactions reported in at least 2% of patients were dyspnea, pneumonia, chronic obstructive pulmonary disease exacerbation, pneumonitis, hypercalcemia, pleural e_usion, hemoptysis, and pain. In NSCLC Trial 3, the most common adverse reactions in patients receiving OPDIVO (reported in 7 at least 20% of patients) were fatigue, dyspnea, musculoskeletal pain, decreased appetite, cough, nausea, and constipation. SPECIAL PRECAUTIONS FOR STORAGE Store OPDIVO under refrigeration at 2 C to 8 C. Protect OPDIVO from light by storing in the original package until time of use. Do not freeze or shake. MARKETING AUTHORISATION HOLDER: Bristol-Myers Squibb Company. Princeton, New Jersey 08543 USA MARKETING AUTHORIZATION NUMBERS Opdivo 40 mg/4 ml (10 mg/ml) 2-960-15. Opdivo 100 mg/10 ml (10 mg/ml) 3-960-15. DATE OF FIRST AUTHORIZATION/RENEWAL OF THE AUTHORIZATION: 01-Sep-2015 DATE OF REVISION OF THE TEXT: SEPT.-2017 BMS International Corporation (Scientific Office) 184 Tahleya St., Aknaz Center, 2nd floor Office# 18, PO. Box: 19870, Riyadh 11445, Saudi Arabia. Tel: +966 11 219 9700, Fax: +966 11 416 9085 Web: www.bms.com 1506SA17PR08580-1

Committee Prof. Abdul Rahman Jazieh, MD, MPH Chairman, ASCO Direct Current Update 2017 (ASCO2017) Chairman, Saudi Lung Cancer Association/ Lung Cancer Academy Chairman, Oncology Department Professor, King Saud University for Health Sciences King Abdulaziz Medical City (KAMC) King Abdullah Specialized Children s Hospital (KASCH) Ministry of National Guard Health Affairs Hassan S. Alorainy, BsRC, RRT, FAARC Executive Director, ASCO Direct Current Update 2017 (ASCO2017) Executive Director, Saudi Thoracic Society (STS) Senior Respiratory Specialist Mission To collaborate and lead national and international initiatives in lung cancer control including prevention, education, research and promotion of evidencebased practice. Vision Become a regional leader and global participant in the fight against lung cancer and contributor to the advancement of knowledge in the field Objectives Facilitate collaboration among health care professionals and organizations with interest in lung cancer Enhance evidence based practice by the development, dissemination and implementation of guidelines relevant to the region Conduct research projects to help better understand and manage lung cancer in the region Participate in lung cancer control initiatives Conduct educational activities for health care professionals and the public Members Joud M. Hajjar, MD, MS Assistant Professor of Medicine Division of Immunology, Allergy and Rheumatology Baylor Colege of Medicine, Texas Children s Hospital Houston, Texas, USA Prof. Mohamed S. Al-Hajjaj, MD, FRCP(C) Professor and Senior Consultant Pulmonary Medicine President, Saudi Thoracic Society (STS) Hamed AlHusaini, MD Consultant, Medical Oncology King Faisal Specialist Hospital and Research Centre Mubarak Al Mansour, MD Associate Dean, Academic & Students Affairs, College of Medicine, Jeddah Section Head, Adult Medical Oncology,Princess Noorah Oncology Center- Jeddah Jeddah, Saudi Arabia Aung Naing, MD, FACP Associate Professor Department of Investigational Cancer Therapeutics Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, Texas, USA Abdul Rahman Alshehri, MD Consultant, Adult Medical Oncology Department of Oncology King Abdulaziz Medical City Ministry of National Guard Health Affairs Ashwaq Al Olayan, MD Director, MENA NCCN Coordinating Center Consultant, Adult Medical Oncology Department of Oncology King Abdulaziz Medical City Ministry of National Guard Health Affairs 7

faculty faculty Jawaher Ansari, MBBS Consultant, Medical and Radiation Oncology Prince Sultan Military Medical City Ali Alfakeeh, MD Consultant Medical Oncology King Fahad Medical City, Comprehensive Cancer Centre Khalid Alsaleh, MBBS, FRCPC, FACP, MSc, CIP Assistant Professor, Hematology and Medical Oncology Internal Medicine Department, College of Medicine, King Saud University (KSU) Abdullah AlSharm, MD Chairman, Adult Medical Oncolgy Department King Fahad Medical City, Riyadh Prof. Medhat Faris, MD, DMRT, ESMOc Consultant Medical Oncology King Fahad Specialist Hospital Dammam, Saudi Arabia Hamed AlHusaini, MD Consultant, Medical Oncology King Faisal Specialist Hospital and Research Centre Joud M. Hajjar, MD, MS Assistant Professor of Medicine Division of Immunology, Allergy and Rheumatology Baylor Colege of Medicine, Texas Children s Hospital Houston, Texas, USA Fahad IbnShamsah, MD Consultant, Adult Medical Oncology Chairman, Adult Medical Oncology, Oncology Center Director, Outreach Program King Fahad Specialist Hospital Dammam, Saudi Arabia Abdul Rahman Alshehri, MD Consultant, Adult Medical Oncology Department of Oncology King Abdulaziz Medical City Ministry of National Guard Health Affairs Ahmad Al Zahrani,MD Consultant Medical Oncologist King Faisal Specialist Hospital and Research Center Abdullah AlTwairqi, MD Consultant, Adult Medical Oncology, King Fahad Medical City Jamal Eldeen Zekri, MD Associate Professor, Alfaisal University- Riyadh Consultant Medical Oncology King Faisal Specialist Hospital & Research Centre - Jeddah Jeddah, Saudi Arabia Mervat Mahrous, MD, VSCRD, CCF (CAN) Oncology Consultant King Fahad Hospital, El-Madina, KSA Associate Professor of Clinical Oncology, Mina University, Egypt El- Madina, Saudi Arabia Mubarak Al Mansour, MD Associate Dean, Academic & Students Affairs, College of Medicine, Jeddah Section Head, Adult Medical Oncology,Princess Noorah Oncology Center- Jeddah Jeddah, Saudi Arabia Aung Naing, MD, FACP Associate Professor Department of Investigational Cancer Therapeutics Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, Texas, USA Ameen Alomair, MD Consultant Radiation Oncology, King Faisal Cancer Center, King Faisal Specialist Hospital & Research Centre Ashwaq Al Olayan, MD Director, MENA NCCN Coordinating Center Consultant, Adult Medical Oncology Department of Oncology King Abdulaziz Medical City Ministry of National Guard Health Affairs 8

SCIENTIFIC Program DAY 1 - FRIDAY, 24 November 2017 SCIENTIFIC Program DAY 1 - FRIDAY, 24 November 2017 Session 1: IMMUNO-ONCOLOGY / DEVELOPMENT OF THERAPEUTICS Moderators: Dr. Ashwaq Al Olayan Prof. Khaled Al Kattan 13:30-14:00 Registration 16:40-17:00 Update in Management of Early Breast Cancer Adjuvant Pertuzumab plus Trastuzumab for HER2-Positive Early Disease APHINITY trial (abstract LBA500) Olaparib for Patients with HER2-Negative BRCA-Mutated Disease OlympiAD trial (abstract LBA4) Dr. Mervat Mahrous 14:00-14:20 Precision Medicine in the Era of Immuno-Oncology Dr. Aung Naing 14:20-14:40 Biomarker of Immunotherapy Dr. Joud Hajjar 14:40-15:00 Future Direction of Immuno-Oncology Dr. Aung Naing 17:00-17:20 Bone Health and Cancer Role of Bone-Modifying Agents in Metastatic Breast Cancer Update Evaluating the impact of bone-targeted agents in the era of novel androgen targeted therapy for metastatic castrationresistant prostate cancer Dr. Medhat Faris Mining for Treatment Options in Recurrent/Metastatic Head and Neck Cancer Dr. Arif Adnan Shawkat 15:00-15:30 Roche Sponsored Session 17:20 15:30-16:00 COFFEE BREAK 19:00 Gala Dinner Session 2: BREAST CANCER Moderators: Dr. Ahmad Al Faraj 16:00-16:20 16:20-16:40 Update in Management of ER Positive Advanced Breast Cancer Abemaciclib for HR-positive/ HER2-Negative Metastatic Breast Cancer (Abstract 1000) Update on CDK 416 inhibitors Immunotherapy in Breast Cancer Neoadjuvant Pembrolizumab for HER2-Negative Breast Cancer (Abstract 506) Durvalumab and tremelimumab in metastatic breast cancer (MBC): Immunotherapy and immunopharmacogenomic dynamics. Dr. Abdul Rahman Alshehri Dr. Khalid Alsaleh Thoracic Oncology Forum TOF2018 The 6 th Annual Scientific Conference of the Saudi Lung Cancer Association (SLCA) 4-5 May 2018 Jeddah, Saudi Arabia ORGANIZED BY: mark your calendar 10 11

SCIENTIFIC Program DAY 2 - SATURDAY, 25 November 2017 SCIENTIFIC Program DAY 2 - SATURDAY, 25 November 2017 08:30-09:00 Registration Session 3: LUNG CANCER Moderators: Dr. Ahmed Abdelwarith Dr. Ahmed Bamousa 09:00-09:20 09:20-09:40 Stage II-III Lung Cancer ADJUVANT: Phase III Trial Evaluating Gefitinib vs Vinorelbine/ Cisplatin in Completely Resected Stage II-IIIA (N1-N2) NSCLC with EGFR Activating Mutations abstract 8500»» Adjuvant Durulumab in Lung Cancer Targeted Therapy ALEX: Alectinib vs Crizotinib as First-Line Therapy in Patients with ALK + NSCLC: Abstract LBA9008 ARCHER 1050: First-Line Dacomitinib vs Gefitinib in EGFR- Mutant Advanced NSCLC: Abstract LBA9007 AURA-3: CNS Response to Osimertinib in EGFR T790M+ Advanced NSCLC: Abstract 9005»» Osimertinib First Line Study Dr. Jawaher Ansari Dr. Hamed AlHusaini 09:40-10:00 10:00-10:20 Immunotherapy in Metastatic Lung Cancer Immunotherapy in Metastatic Lung Cancer Progression After the Next Line of Therapy (PFS2) and Updated OS Among Patients with Advanced NSCLC and PD-L1 TPS >=50% enrolled in KEYNOTE-024 Atezolizumab Treatment Beyond Disease Progression in Advanced NSCLC: Results from the Randomized Ph III OAK Study First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G New Development in Radiation Therapy New Radiation Technique in Early Non-Small Cell Lung Cancer»» Pro-cons of choice of ablative modality - Part of the Oligometastatic NSCLC Session. 10:20-10:40 Q & A, Panel Discussion Dr. Abdullah AlTwairqi Dr. Ameen Alomair 11:10-11:30 11:30-11:50 11:50-12:10 Session 4: GI Moderators: Dr. Azzam Khankan Dr. Abdullah AlZahrani Pancreas Randomized Phase 2 Study of PEGHPH20 Plus nab- Paclitaxel/ Gemcitabine (PAG) vs. nab-paclitaxel/ Gemcitabine (AG) in Patients with Untreated, Metastatic Pancreatic Ductal Adenocarcinoma Colon Cancer Prospective Pooled Analysis of Six Phase III Trials Investigating Duration of Adjuvant Oxaliplatin-Based Therapy (3 vs. 6 months) for Patients with Stage III Colon Cancer: The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration Hepatocellular Carcinoma Phase III Multicenter Open-Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) vs. Sorafenib in Locally Advanced Hepatocellular Carcinoma: The SIRveNIB Study Dr. Ahmad Al Zahrani Dr. Fahad IbnShamsah Dr. Jamal Zekri 10:40-11:10 COFFEE BREAK 12:10-12:30 Q & A, Panel Discussion 12:30-13:30 LUNCH 12 13

SCIENTIFIC Program DAY 2 - SATURDAY, 25 November 2017 SCIENTIFIC Program DAY 2 - SATURDAY, 25 November 2017 Session 5: GU / Sarcoma / Other Malignancies Moderator: Dr. Mohammad Algarni Dr. Emad Tashkandi 13:30-13:50 13:50-14:10 14:10-14:30 14:30-14:50 Sarcoma Alliance A091401: A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma Multicenter Phase II Study of Pembrolizumab in Advanced Soft Tissue and Bone Sarcomas: Final Results of SARC028 and Biomarker Analyses Multi-institutional European single-arm phase II trial of Pazopanib in advance malignant/dedifferentiated Solitary Fibrous Tumors (SFT). A Collaborative Spanish (GEIS), Italian (ISG) and French (FSG) Sarcoma Groups Study Management of Bladder Cancer Updated Survival Analysis From KEYNOTE-045: Phase 3, Open-Label Study of Pembrolizumab Versus Paclitaxel, Docetaxel, or Vinflunine in Recurrent, Advanced Urothelial Cancer»» IMvigor211: A Phase III Randomized Study Examining Atezolizumab vs. Chemotherapy for Platinum-Treated Advanced Urothelial Carcinoma Prostate & Kidney Cancer LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476)»» First Line Nivolumab + Ipilumumab in metastatic renal cell carcinoma Management of Merkel Cell Tumor Avelumab in chemotherapy-refractory metastatic Merkel cell carcinoma: Subgroup analysis of efficacy First-line (1L) avelumab treatment in patients (pts) with metastatic Merkel cellcarcinoma (mmcc): Preliminary data from an ongoing study Avelumab (MSB0010718C; anti-pd- L1) in patients with metastatic Merkel cell carcinoma previously treated with chemotherapy: Results of the phase 2 JAVELIN Merkel 200 trial Dr. Ashwaq Al Olayan Dr. Abdullah Al Sharm Dr. Mubarak Al Mansour Dr. Ali AlFakeeh 14:50-15:10 Q & A, Panel Discussion 15:10 ADJOURNMENT 14

ONC-LLY-00013- SA-10/16 THE ONLY THING MORE RELENTLESS THAN CANCER IS THE PEOPLE WHO FIGHT IT. Because no two cancer patients are alike, Lilly Oncology is committed to developing a broad portfolio of therapies, including those tailored to unique patients, and meaningful support solutions that accelerate the pace and progress of cancer care. Find out more at LillyOncology.com. For more information, pleae contact Eli Lilly and Company Scientific Office:Olaya Towers, Tower B, Building No. 3074, 16th Floor, Prince Mohamed Ibn Abdulaziz Street, Olaya, Riyadh 11653. Kingdom of Saudi Arabia Tel : +9664617800

ERS-STS JOINT MEMBERSHIP ERS-STS JOINT MEMBERSHIP FORM Membership Fee: SAR200 EUR50 USD50 Eligible Countries: GCC Countries: Saudi Arabia, Bahrain, Kuwait, Oman, Qatar, and United Arab Emirates. Middle East Countries: Egypt, Sudan, Lebanon, Syria, Jordan, Iraq, Yemen, and Iran. Any other Nationality residing and/ or practicing in any of the above countries. Membership Fee: SAR200 EUR50 USD50 Eligible Countries: GCC Countries: Saudi Arabia, Bahrain, Kuwait, Oman, Qatar, and United Arab Emirates. Middle East Countries: Egypt, Sudan, Lebanon, Syria, Jordan, Iraq, Yemen, and Iran. Any other Nationality residing and/ or practicing in any of the above countries. ERS-STS Joint Membership Benefits 1. The ERS will provide full electronic access to the European Respiratory Journal (ERJ) to all members of STS, except ERS Congress Abstracts and Proceedings supplements of the ERJ, which will be distributed to Congress attendees only. ERS reserves the right to change the format of the ERJ to open access, if needed. 2. The ERS will provide full electronic access to the European Respiratory Review (ERR), Breathe (both currently open access) and the Monograph to all members of STS 3. The ERS will offer all its publications in printed form to all interested members of STS at a special discounted price. 4. The ERS will distribute the ERS Weekly Newsletter to STS members. 5. ERS and STS will proactively co-operate to offer STS members preferred access to ERS Educational Services online and Events, as well as to endorse STS Educational Services by ERS, where applicable. 6. Ordinary, distinguished and honorary members of STS may participate in the constitutional meetings of the ERS and may vote. They are eligible for election to office up to Assembly Head without any residence restriction and eligible for any office position up to ERS Presidency, provided they have their main residence in Europe, according to ERS Constitution and Bylaws in its last approved version. Members of STS are accorded all rights and privileges as detailed in the ERS Constitution and Bylaws in its last approved version. 7. Distinguished Officers of the Executive Committee, members of Governance bodies and members of STS, provided they qualify and they apply for it, duly endorsed by STS, will be considered for election in the prestigious Fellow of ERS program (FERS) Title: Prof. Dr. Mr. Ms. Gender: Male Female First Name: Last Name: Specialty: Current Post: Present Position: Middle Name: Area of Interest: Degrees: (MD, MBBS, PhD, etc...) Date of Birth: (Day / Month / Year) Additional ERS Membership Entitlements 1. Discount on ERS International Congress. Special rates available for: Scientists (PhD, non-md), Allied Health Professionals, Under 35s 2. Special rates on ERS Events 3. Affiliation to up to three groups of your choice in any of our eleven Scientific assemblies 4. Exclusive access to all research proposals 5. Eligible to stand for office and vote for Assembly and Group Officers and to vote at the General Assembly 6. Eligible to propose Symposia for the ERS International Congress 7. Eligible to apply for grants 8. Eligible to apply for financial support when setting up seminars and task forces enables members to produce position papers statements or guidelines that subsequently become the official ERS documents on issues related to respiratory medicine www.ersnet.org Institution: (Name of your Hospital, Med. Center...) City: Country of Residence: Telephone No.: Mobile No.: (Include Country Code) Email Address: Region: Nationality: Fax No.: STS Membership Benefits 1. The opportunity to chair sessions in Society s meetings and active participation in scientific committees related to the member s experience and academic interest. 2. Free or discounted admission to all STS scientific activities (Symposiums, Conferences, medical meetings with credit hours etc...). 3. Free subscription to Annals of Thoracic Medicine ATM; www.thoracicmedicine.org, the scientific journal of STS. 4. Obtaining all brochures, handouts, and booklets of STS for FREE. 5. Getting the monthly Pulmonary Medicine updates & abstracts. 6. Free subscription to the STS Arabic Magazine Al.Tanafus. 7. Free admission to the monthly Chest Club meetings with credit hours. 8. Receiving all STS scientific materials including local guidelines and medical books in the field of chest diseases. 9. Email Alerts to all scientific events in the Kingdom and the world. www.saudithoracic.com Alternate Email Address: ERS Membership Number: (if any) SCFHS: (if any) Signature: Date: www.saudithoracic.com / www.ersnet.org

The Official Publication of Saudi Thoracic Society Saudi Thoracic Society (STS) is a scientific foundation and a leading resource for improvement of lung health in Saudi Arabia. Its mission is to promote the prevention, diagnosis, and treatment of chest diseases through leadership, education, research, and communication. STS was established in 2002 and it is affiliated with King Saud University in Riyadh. The specific aims of the Society are: SUBSIDIARIES Promoting and coordinating activities in the field of respiratory medicine. Fostering research activities in the field of respiratory medicine. Organizing and coordinating regular national and regional meetings. Publishing a newsletter and a journal of international repute. Publishing and updating clinical practice guidelines in the field of respiratory medicine. No processing or publication fees A friendly free online submission system na l P Gr Saudi gy Submission - Decision time is 45 days only e r vent io olo Initial review by the board within a week nt r I on Indexed in more than 30 searchengines fo lm Available in Pubmed p u A leading Journal in Thoracic Medicine with an impact factor of 1.529 ou A peer review and open access journal SGIP You are invited to become a member of the Joint STS-ERS Membership. You will be ORM F P I a valuable member of our mailing list ERSH B M E and it is important to keep Uni NT M you informed I r, and O J, Qata n,y S a q T on relevant updates, articles, news and a m Ir O S rdan, wait, S o u J K, R, ve ia E e abo ahrain n, Syr es: bano bia, B y of th announcements. e untri a n L r o a, A n i C in ing Suda ible Saud, ctic Elig tries: Egypt or pra Fee: Coun tries: C n and/ u C o g G C Male in t s id s a e le E ty r der: n Midd her Nationali e G t Ms. Any o r. M me: le Na Dr. Midd of B Prof. Date Title: hip bers Mem 0 0 2 SAR 0 4 R U E 0 USD5 To Register, kindly visit our website (www.saudithoracic.com) First e: Nam : e Nam Last www.thoracicmedicine.org : ialty www.saudithoracic.com Spec ost: ent P Area t: teres of In ees: Degr (MD, ), etc..., PhD MBBS

SPONSORs SPONSORs PLATINUM SPONSORS SILVER SPONSOR Bristol-Myers Squibb is a global BioPharma company firmly focused on its Mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Around the world, our medicines help millions of people in their fight against such diseases as cancer, cardiovascular disease, hepatitis B, HIV/AIDS, rheumatoid arthritis and psychiatric disorders. At Bristol-Myers Squibb, our BioPharma strategy uniquely combines the reach of a major pharma company with the enterpreneurial spirot and agility of a successful biotech company. With this strategy, we focus on our customers needs, giving maximum priority to accelerating pipeline development, delivering sales growth and continuing to manage costs. For more than five decades, Lilly Oncology has been dedicated to delivering innovative solutions that improve the care of people living with cancer. Our heritage serves as inspiration to continue developing lifechanging medicines and offering support to the people we serve. We re determined to continue making life better for all those affected by cancer around the world. Lilly Oncology is dedicated to advancing treatment and addressing the unmet needs of people living with cancer. Building on our work in cancer treatment, we are committed to creating a broad portfolio with research focused in three areas tumor cell signaling, microenvironment, and immuno-oncology and exploring different combinations and sequencing of therapy so we can help advance treatment for more people. Our hope is to optimize cancer patient outcomes and find meaningful and practical ways to support patients, caregivers, and the care team throughout the cancer journey. Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI). Bronze SPONSOR AstraZeneca is a British Swedish multinational pharmaceutical and biologics company headquartered in London. We have a portfolio of products for major disease areas including cancer, cardiovascular, gastroinstestinal, infection neuroscience, respiratory, inflammation & Metabolic diseases. Our Purpose: We push the boundaries of Science to deliver the life-changing medicines. Together, we can be confident that, by leading in science, we will transform the lives of patients around the world. Pascal Soriot, CEO AstraZeneca The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. 22 23

SAPH2018 DUBAI 2018 T h e 1 1 Th A n n u A l C o n f e r e n C e o f The SAudi ASSoCiATion for PulmonAry hypertension 14-17 MARCH INTERCONTINENTAL - FESTIVAL CITY 5-7 April 2018 DubAi, uae target audience: Adult/ Pediatric Pulmonologists Cardiologists Rheumatologists Cardiac Surgeons Neonatologists Intensivists Internists Pathologists Radiologists Pharmacologists Researchers in the field Fellows in Training Technologists Nursing The 9th Annual Congress of Saudi Thoracic Society in Collaboration with Emirates Allergy and Respiratory Society organized by: topics include: Update from the 6 World PH Symposium. PH Diagnosis, Classification and Management Pulmonary Hypertension in Children Treatments Pathways PH and Rheumatic Diseases Debates; Pro & Cons Round Table Discussion Congenital Heart Disease Current Update on CTEPH Emerging Therapies and Interventional Modalities Challenging Cases and Abstracts Session th ABOUT US: The GulfThoracic Congress 2018 is the ninth joint meeting of the Saudi Thoracic Society (STS), in collaboration with Emirates Allergy and Respiratory Society (EARS), American Thoracic Society (ATS), European Respiratory Society (ERS), Meakins-Christie Laboratories- McGill University, Canada and European Society of Thoracic Surgeons (ESTS). With special participation from The Cleveland Clinic Foundation, USA, The Royal Brompton and Harefield Hospitals, UK, and Saudi Society for Respiratory Care (SSRC). in collaboration with: To investigate the local incidence, prevalence, and pathobiology of PVD in the region. To identify local characteristics of the illness including its morbidity and mortality. To develop/ update national guidelines for the diagnosis and treatment of PVD. To provide expertise that will address issues related to the education and training of healthcare professionals in the field of PVD. To focus on improving the diagnosis and management of PVD, by promoting basic and clinical research. To promote public awareness through different means including print and electronic media, and public seminars. sponsored by: As usual, for the main program the Scientific Committee is planning a very comprehensive Scientific Program catering for all specialties of Pulmonary/ Thoracic Medicine covering state-of-the-art Lectures, Update Presentations, Workshops, Panel Discussions, Interactive Sessions, Master Clinician Sessions, Challenging Clinical Cases, and Research Abstract Presentations. MSF2018 WORKSHOPS & COURSES: All specialties related to Thoracic Medicine which includes but not limited to: Pulmonologists, Thoracic Surgeons, Allergist & Immunologist, Intensivists, Respiratory Oncologists, Internists, Physicians, Radiologists, Pharmacists, Scientists, Respiratory Care Specialists, Technologists, Nursing Staff, Medical Students, as well as advocates and Researchers in Public Health and Health Promotion including Environmental and Occupational Health. OUR MAIN SPONSORS: TSF2018 SCFHS 30CMEs SCfHS CMEs are IN PROCESS www.gulfthoracic.com Pulmonary Function Testing Workshop Bedside Thoracic Ultrasound Workshop Thoracic Imaging Workshop Endobronchial Ultrasound and Conventional Bronchoscopic Procedures Workshop Research Methodology Workshop Thoracic Surgery Forum thank you for your support. Telephone: (+966) 11 462 2515 Ext. 12 Mobile: (+966) 53 390 0411 Email: saphsts@gmail.com Asthma and COPD Pulmonary Infections Interstitial Lung Diseases Pulmonary Hypertension Pleural Diseases Chest Imaging Sleep Medicine Critical Care Medicine Interventional Pulmonology Respiratory Care Thoracic Oncology Thoracic Surgery Pediatric Pulmonology Research in Pulmonary Medicine Venous Thromboembolism Abstracts Oral Presentations Medical Students Forum WHO SHOULD ATTEND your registration will help us estimate attendance and hence better planning for all. www.saph-sts.com dear colleagues, if you plan to attend this event, please take a moment of your valuable time to complete a simple registration form at: www.saph-sts.com/saph2018. GT2018 will be held at the InterContinental-Dubai Festival City, UAE on 14-17 March 2018. This year, GT2018 will be featuring once again the Thoracic Surgery Forum (TSF2018) and Medical Students Forum (MSF2018). We also are happy to be hosting the 20th Annual Meakins-Christie International Symposium on Asthma and COPD- McGill University, Canada. saph objectives: TOPICS INCLUDE: The 20th Annual Meakins-Christie International Symposium on Asthma and COPD

ASCO Direct Current Update 2017 24-25 November 2017 Crowne Plaza Hotel, Jeddah, KSA Conference Secretariat: (+966) 11 462 2515 Ext. 14 (+966) 53 390 0404 slca.lca.sts@gmail.com Saudi Lung Cancer Association (SLCA)/ Saudi Thoracic Society 2017, All Rights Reserved